Tags Posts tagged with "$IMLFF"


0 2631
Marjuana-Stocks-cannabis biotech

Although the biotech industry is poised to be one of the greatest beneficiaries of the legal cannabis movement, investors must be cautious with many of the companies focused on this opportunity.

While opportunity is vast, it is also expensive and many of these companies do not have the capital needed to execute on its strategy. We have highlighted three biotech cannabis firms below in order of favorability and will continue to monitor how they execute on their plan from here.

The Good, The Bad, And The Ugly

Yesterday, InMed Pharmaceuticals, Inc. (IN.CN) (IMLFF) announced a major step in its strategy after it entered a R&D collaboration with ATERA SAS of France.

Unlike some its competitors, InMed is focused on partnering with top-notch organizations and ATERA is a leading tissue engineering company specializing in the development of advanced human tissue models.

Under the terms of the agreement, ATERA will evaluate the efficacy of InMed’s lead compound, INM-750 and will investigate the beneficial effects of topically applied INM-750 at ultra-structural cellular and molecular levels.

Today, Israeli based Therapix Biosciences (TRPX) and CURE Pharmaceutical (CURR) signed a memorandum of understanding to enter a research collaboration with Israel’s largest private medical services center, Assuta Medical Centers. The companies will collaborate to advance, research, develop and commercialize potential therapeutic products in the fields of personalized medicine and cannabinoids.

Under the agreement, the companies intend to formalize the pooling of professional, scientific, financial resources and expertise, to benefit from each of its respective advantages and capabilities to develop new therapeutic products in the fields of personalized medicine and cannabinoids. Specifically, CURE and Therapix will provide support and expertise in the development of pharmaceutical products, while Assuta will support the early research and development of potential projects through its research and facilities.

NEMUS Bioscience, Inc. (NMUS) had another setback today and issued an update in regards to a private placement with Schneider Finance LLC for the sale of 1,000,000 shares of Series E Preferred Stock for gross proceeds of $20,000,000.

The financing was supposed to close by today and as of today, Schneider Finance LLC did not provide funding to close the transaction and requested an extension of the closing date. NEMUS plans to continue to work with Schneider Finance to close the transaction.


Authored by: Jason Spatafora

1 5874

Cannabis stocks have come down from their recent highs and this has raised some concerns after we ended 2016 on a high note.

2016 was a great year for the cannabis industry and we expect 2017 to build off this success. From Canada to Australia, the United States to Germany, the global cannabis industry continued to expand and the stage is set for growth for years to come.

The recent weakness has led to an influx of questions pertaining to the top cannabis investment opportunities and we want to highlight 7 cannabis stocks that investors should watch during 2017.

Seven Cannabis Stocks to Watch

1. GW Pharmaceuticals (GWPH): We continue to view GWPH as the top long-term biotech investment levered to the cannabis industry and we expect to see a VERY STRONG second half of the year. We are favorable on the long-term outlook due to its deep pipeline of products in advanced stages of clinical trials, its strong balance sheet, and its favorable Wall Street coverage.

2. Zynerba Pharma (ZYNE): We consider the company to be one of the most undervalued biotech investment opportunities. Zynerba is focused on developing treatments from synthetic cannabis and the average Wall Street price target offers almost 100% upside to current levels.

3. Canopy Growth (WEED.TO) (TWMJF) continues to be the leader in the Canadian medical cannabis industry and view the company as one the best opportunities within the cannabis industry. The shares have been trending lower and we view this weakness as a great opportunity to buy into a high-quality cannabis producer with a global footprint.

4. Emblem Corp. (EMC.V) (EMMBF) has been trending so far this year and the shares are down 30% during this time. Despite the recent weakness, we are bullish on the company’s opportunity due to its attractive business model, its proven management team, its sound financial structure, its strong balance sheet, and its leverage to growth trends in the cannabis sector

5. After securing a potentially highly lucrative licensing contract, InMed Pharmaceuticals, (IN.CN) (IMLFF) looks even better positioned to benefit for positive tailwinds facing the global cannabis industry. InMed is a pre-clinical biopharmaceutical company that is focused on the research and development of novel and cannabinoid-based therapies in Canada. The company has a strong pipeline of products in various stages of FDA testing and is developing various drugs for diseases, such as ocular, pain and inflammation.

6. VPR Brands, LP, (VPRB) is a stock to watch as it is levered to several growth trends within the global cannabis industry. The shares have pulled back and we see upside to current levels. In 2016, VPR acquired Vapor Corp’s wholesale operations and assets for a significant discount and recent announcements show that VPR has executed on and monetized this acquisition. We view this as a very attractive growth story that is undervalued by the street.

7. Vinergy (VIN.CN) (VNNYF) has been one of the most interesting and exciting stories to watch over the last six months and we see significant upside to current levels. The shares have fallen more than 33% in the last month and we find them to be attractive due to the number of catalysts for growth over the next year.

Pursuant to an agreement between MAPH and InMedPharmaceuticals., we were hired for a period beginning February 24 2017 and ending April 24, 2017 to publicly disseminate information about (IMLFF) including on the Website and other media including Facebook and Twitter. We are being paid $40,000 (CASH) for and were paid “250,000” shares of restricted common shares of InMed Pharmaceuticals.Pursuant to an agreement between MAPH and VPRBrands, we were hired for a period of 90 days to publicly disseminate information about (VPRB) including on the Website and other media including Facebook and Twitter. We are being paid $45,000 (CASH) for or were paid “ZERO” shares of unrestricted or restricted common shares. We own zero shares of (VPRB) which we purchased in the open market. Pursuant to an agreement between MAPH and a non-affiliate third party, we were hired for a period of 2 months to publicly disseminate information about (VNNYF) including on the Website and other media including Facebook and Twitter. We are being paid $120,000 (CASH) for or “ZERO” shares of restricted or unrestricted common shares. We own zero shares of (VNNYF) which we purchased in the open market. We may buy or sell additional shares of (IMLFF, VPRB, VNNYF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

0 5068

As you may or may not know I love Biotech companies as investment opportunities! The reason being is the fact they trade unlike any other companies out there and there are tangible milestones they can hit which when positive send the market into a buying frenzy. In the last year I’ve written about GWPH, ZYNE and CARA which are all Big Board (Nasdaq) companies in Forbes quite successfully and ahead of the market. Today I am writing about INMED, a Canadian based biotech company with board members from Eli Lilly, MIT and a Chief Medical officer formerly of GW Pharmaceuticals who will be the focus of this interview.

InMed has already distinguish themselves as a leading Cannabinoid Pharmaceutical Company. As one of very first biotech companies that entered the Cannabinoid research space, they are uniquely positioned capitalize on the anticipated growth of the cannabis-derived pharmaceutical market by creating not just therapies, but efficient scientific procedures to create those drugs and more importantly patent new methods in the process that are bankable & universal for other companies.

Today I am pleased to bring to the subscribers of Marijuanastocks.com an exclusive interview InMed’s Chief Medical Officer; Dr. Ado Muhammed, MD, DPM, MFPM.

He knows a few things about with cannabinoid based drugs as he is the former Assoc. Medical Director for GW Pharmaceuticals. GW Pharma and was part of the development team that developed Sativex, a cannabinoid based drug for MS that has been approved in over 15 countries worldwide.

Dr. Muhammed is a proven leader in the development of cannabinoid therapies, having played a strategic role in the clinical development, R&D, and commercialization of these specialty drugs.

I asked him to explain what InMed is doing and what separates them from Pack.

Q: What initially attracted you to join InMed an earlier stage biotech company involved in cannabis based Pharmaceuticals…an area you have a unique perspective on?

A: Initially it was InMed’s approach to drug discovery using their Bioinformatic program. This precision in the discovery process was a far more advanced approach than I had seen before in my career. The ability to discover compounds intelligently and efficiently to treat disease creates a significant industry advantage for InMed. Also, their drug delivery approach- avoiding systemic exposure through topical/local delivery I believe has a therapeutic advantage over oral delivery in terms of safety and efficacy.

Q: What differentiates InMed from other leading cannabinoid Biotech companies that you have seen?

In addition to the bioinformatics I see two other areas where InMed has an industry advantage. Firstly, using plant equivalent compounds versus others developing synthetic compounds is a clear advantage in my opinion. This will improve the safety profile of InMed’s therapies while providing the efficacious results expected in the treatments. Secondly, the ability to produce cannabinoids in the biosynthesis process

On the other spectrum InMed’s natural compound approach using specifically identified cannabinoids is also unique. This approach vs others using whole plant extracts and oils, is a more efficient method in terms of clinical development. Efficiency in time and cost

A: I understand you were at UBC yesterday getting an update from the team on the biosynthesis program. What essentially is this program and why is it so important for InMed and its shareholders?

Q: Essentially biosynthesis is a process that can manufacture cannabinoids out of a biologic system. This is a well-known system, as evidenced in the manufacturing of insulin, which is used by millions of diabetics daily. Again, I will point to efficiency and precision. Manufacturing cannabinoids in a controlled laboratory environment and eliminating the significant costs and variables associated with the current methods. This will have a major impact on both drug quality & costs. Also, the ability to produce all of the 90+ cannabinoids at a uniform cost open up InMed’s therapeutic potential and will secure our position as a world leader in cannabinoid prescription drug development.

Q: Fast forward 3 years…what are your top 3 indications

A: Of course, Epidermolysis Bullosa our lead therapy. We would expect to be in Phase 3 trials within 3 years and moving quickly to registration. Glaucoma we are targeting to have advanced to a stage where it can be partnered within the next 12 months. I also predict our advancement of other indications within the dermatology/orphan drug space, including the treatment of acute and chronic pain using a topical approach.

4.) Final Thoughts on InMed for our subscribers?

a. InMed has created a tremendous amount of value in a short period as evidenced by the assets in this company. InMed has the opportunity to become a world leader in cannabinoid based medicines and we are well on our way. The team we have assembled has both experience and capabilities to execute on this ambitious goal.


The Cannabis Biotech/Pharma Market Could Surpass $20 Billion by 2020, and while we see the MJ licensed growers offering “medical” marijuana” The big winners in the Cannabis financial space will clearly be the Biotech’s like GWPH, ZYNE, CARA and Vancouver Biotech IMLFF. If you are not familiar with how the US cannabis industry is being tilted towards pharma companies I suggest you read this.

InMed (IMLFF) is a company I have known for a while, actually since I got involved in this space. When I first heard about them and met them two years ago I thought to myself “I wonder how far along they will be in two years?” Well 2 years later and they are positioning themselves in MY OPINION for Buyout or Biotech Glory. They are the frontrunner for Cannabis based Biotech in Canada, but more importantly…….

INMED is completely insulated by Federal, Country or State Law as it relates to Cannabis because at the end of the day they are science based nerds that happen to be mapping the Genome of pot!

0 1271

InMed Expands Pipeline with Initiation of Program Targeting Epidermolysis bullosa simplex (EBS)

Pre-clinical studies of INM-750 to commence February, 2015Third Program Discovered Through InMed’s Proprietary Drug Design Platform

VANCOUVER, British Columbia, Feb. 3, 2015 /PRNewswire/ – InMed Pharmaceuticals Inc. (“InMed”) (CSE: IN; OTCQB: IMLFF) announced today that it has added a new therapy to its pipeline: INM-750, for the treatment of Epidermolysis bullosa simplex(EBS), a rare genetically inherited skin disorder. INM-750 is designed to suppress pathological skin growth, differentiation and inflammation that are signature characteristics of EBS.

InMed anticipates commencing pre-clinical studies of INM-750 in February, 2015 with initial data expected by Q2 2015. The initiation of INM-750 signals InMed’s entry into the dermatological market and adds to the Company’s rapidly advancing pipeline of cannabis-based therapeutics, which includes CTI-805 for glaucoma and CT-091 for arthritis, both of which are expected to enter human clinical studies in 2015.

“We are pleased to continue the strategic diversification of our pipeline by adding a third therapy identified by our proprietary platform technology,” said Craig Schneider, President & CEO of InMed. “The discovery of INM-750 furthers our corporate strategy of developing therapies for diseases that may be approved for Orphan Drug Designation.”

Sazzad Hossain, Ph.D., M.Sc., Chief Scientific Officer of InMed, stated, “EBS is a rare keratin mutation-related disease with no FDA approved treatment. The only options available to patients are wound care, pain management, and preventative bandaging. More severe forms of the disease lead to scarring, disfigurement, disability, and early death, usually before the age of 30.”

Craig Schneider concluded, “We are working rapidly to advance the development of INM-750 to address this significant unmet medical need.”

About Epidermolysis bullosa simplex (EBS)

Epidermolysis bullosa simplex (EBS) is Epidermolysis bullosa simplex (EBS) is one of the major forms of Epidermolysis bullosa a group of genetic conditions that cause the skin to be very fragile and to blister easily. It is a result of a defect in anchoring between the epidermis and dermis, resulting in friction and skin fragility. Its severity ranges from mild to lethal. As of today there is no cure or effective treatment. Currently, wound care, pain management and preventative bandaging are the only options available for treatment. The more severe forms of the disease lead to scarring, disfigurement, disability and early death, usually before the age of 30.

About InMed

InMed is a clinical stage biopharmaceutical company that specializes in developing novel therapies through the research and development into the extensive pharmacology of cannabinoids coupled with innovative drug delivery systems. InMed’s proprietary platform technology, product pipeline and accelerated development pathway are the fundamental value drivers of the company. For more information, visitwww.inmedpharma.com.


InMed Pharmaceuticals Inc.
Craig Schneider
President and Chief Executive Officer
Tel:  604.669.7207
Fax: 604.683.2506
info@inmedpharma.com / www.inmedpharma.com

Tiberend Strategic Advisors, Inc.
Joshua Drumm, Ph.D. (Investors)

Amy Wheeler (Media)

Forward Looking Statements

This news release may contain forward-looking statements and information based on current expectations.  These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, there can be no assurance that such assumptions will prove to be correct.  We assume no responsibility to update or revise them to reflect new events or circumstances.

Additionally, there are known and unknown risk factors which could cause InMed Pharmaceuticals actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking information contained herein.

All forward-looking information herein is qualified in its entirety by this cautionary statement, and InMed Pharmaceuticals disclaims any obligation to revise or update any such forward-looking information or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

These risks and uncertainties include, among others, the possibility that clinical trials will not be successful, or be completed, or confirm earlier clinical trial results, risks associated with obtaining funding from third parties, risks related to the timing and costs of clinical trials and the receipt of regulatory approvals.


To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/inmed-expands-pipeline-with-initiation-of-program-targeting-epidermolysis-bullosa-simplex-ebs-300029646.html

Subscribe Now & Begin Receiving Marijuana Stocks News, Articles, Trade Alerts & MORE, all 100% FREE!

We are your #1 source for all things Marijuana Stocks, Subscribe Below!

Privacy Policy: We will NEVER share, sell, barter, etc. any of our subscribers information for any reason ever! By subscribing you agree we can send you via email our free e-newsletter on marijuana stocks related, articles, news and trade alerts. Further questions please contact privacy@marijuanastocks.com
Ad Placements